Drug & Biologic Risk Assessment
Physician-led scoring for small molecules, biologics, and cell & gene therapies across NDA, ANDA, 505(b)(2), and BLA pathways. Trial-design integrity, endpoint validity, CMC, and exclusivity strategy — in 24–48 hours.
The Problem
Pivotal endpoints that look strong on paper fall apart under ICH E9(R1) scrutiny. Exclusivity windows collapse when a paragraph-IV challenge lands. CMC scale-up kills launches no one saw coming. Vantage surfaces these pre-LOI.
Pivotal trial hit statistical significance, but the primary endpoint doesn't translate cleanly to labeling or payer coverage. FDA advisory committees routinely unwind this.
Orphan + NCE + pediatric exclusivity can look like a 12-year moat — until a paragraph-IV ANDA lands or a 505(b)(2) competitor threads a workaround. Real LOE is often years shorter.
A process validated at 100L doesn't always work at 10,000L. Bioreactor drift, fill-finish capacity, and single-source raw materials kill launch timelines more often than clinical does.
Standard of care moves between trial start and launch. Your active comparator may no longer be relevant, and payer coverage hinges on comparative effectiveness.
Accelerated approval, REMS, and confirmatory-trial obligations become expensive surprises. Track record on timely fulfillment is public — most sellers don't surface it.
Sole-source small molecules become eligible 7 years post-approval, biologics at 11. Exposed assets have materially different DCFs than the pitch deck shows.
Regulatory Pathways We Cover
An NDA isn't an ANDA isn't a 505(b)(2) isn't a BLA. Each has its own risk surface — reference listed drug integrity, trial-design acceptability, CMC bar, exclusivity arithmetic. Our model weights accordingly.
New molecular entities. Pivotal-trial integrity, endpoint strength, safety database, labeling negotiation, and post-marketing commitments drive the risk score.
Relies on published literature or listed reference drug. Risk sits in bridging studies, patent/exclusivity landmines, and reimbursement when the reference drug is genericized.
Bioequivalence-based. Risk is paragraph-IV Hatch-Waxman litigation, API supply, FDA CGMP inspection history, and margin compression on launch.
Protein therapeutics, mAbs, cell & gene therapies. CMC complexity, manufacturing scale, PTC-Purple-Book exclusivity, and biosimilar exposure dominate.
Therapeutic-Specific Score Weights
Same 20-category taxonomy as every vertical. The weights reflect what actually kills therapeutic deals. Clinical and exclusivity get more room. Cybersecurity gets less. Percentage is relative contribution to the composite score.
| Domain | Weight | What we're looking at |
|---|---|---|
| Clinical Trial & Endpoint Integrity | 24% | Pivotal design, endpoint validity under ICH E9(R1), statistical plan, data monitoring, missing-data handling, comparator relevance |
| IP & Exclusivity Strategy | 18% | Composition-of-matter, method-of-use, formulation patents, orange-book listability, orphan/NCE/pediatric exclusivity, paragraph-IV exposure |
| Regulatory Pathway Integrity | 15% | Pre-IND/EOP2/pre-NDA meeting minutes, special protocol assessment, breakthrough/fast-track/priority-review status, foreign regulatory alignment |
| CMC & Manufacturing | 13% | Process validation, API sourcing, fill-finish capacity, comparability protocols, PAI readiness, CDMO dependency, serialization |
| Reimbursement & Payer | 11% | ICER outlook, payer policy precedent, IRA Medicare negotiation exposure, 340B impact, part B vs D, comparative effectiveness positioning |
| Safety & Pharmacovigilance | 9% | Safety database size, adverse-event trends, REMS requirements, boxed-warning risk, post-marketing commitment history |
| Commercial & Market Access | 6% | Prescriber target, channel strategy, specialty pharmacy network, hub services, patient support programs, KOL engagement |
| Financial & Operational | 4% | Runway to approval, R&D spend discipline, licensing obligations, contingent value rights — provided by buy-side |
Pricing Ladder
Start with a Quick Score to triage. Scale up to a full report when the deal moves. Every tier returns in 24–72 hours with named physician + pharmacologist reviewers.
Want continuous monitoring post-close? Surveillance from $1,500/mo →
Therapeutic Intelligence Library
Deep dives on the therapeutic risks that unwind acquisitions. Written by Arvind and Aswini.
Review-division backlog, advisory-committee cadence, and inspection throughput. Which therapeutic programs are structurally at risk in the next 18 months.
Read → Regulatory Shift2026 draft guidance changes what qualifies as confirmatory evidence. Programs that over-invested in traditional Phase 3 may now be overbuilt; others may be underbuilt.
Read → Early AssetLicense terms, march-in rights, sponsored-research publication obligations, and inventor-retained interests. The stuff every TTO forgets to tell the buyer.
Read → Market AccessEligibility criteria, negotiation arithmetic, small biotech exemption, and what a DCF built pre-IRA misses about post-approval cash flow.
Read → ExclusivityThe interaction rules are messy. A stacking mistake costs 2–4 years of exclusivity. How we model the real LOE (loss of exclusivity) date.
Read → Post-MarketingPrograms accelerated on surrogate endpoints carry confirmatory-trial obligations. Missed obligations now trigger FDA withdrawal — not just a strongly worded letter.
Read →Send us the target and a data-room link (or even just a pipeline page). We return a Quick Score in 24 hours. If you want to start with a call first, we'll make time today.